Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

86.46
+0.29000.34%
Volume:14.19K
Turnover:1.22M
Market Cap:16.88B
PE:19.79
High:86.70
Open:85.65
Low:85.65
Close:86.17
52wk High:92.86
52wk Low:53.56
Shares:195.28M
Float Shares:163.04M
Volume Ratio:0.61
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.37
EPS(LYR):0.1575
ROE:24.30%
ROA:11.52%
PB:4.05
PE(LYR):549.04

Loading ...

Barclays Sticks to Its Buy Rating for Incyte (INCY)

TIPRANKS
·
5 hours ago

Incyte Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
16 hours ago

Incyte (INCY) Gets a Hold from Truist Financial

TIPRANKS
·
Yesterday

Cautious Optimism for Incyte’s Early-Stage Cancer Therapies: Hold Rating Pending Further Data

TIPRANKS
·
Yesterday

Incyte announces clinical data on TGFbetaR2PD-1 bispecific antibody

TIPRANKS
·
Yesterday

Incyte Unveils Promising Early Results for Novel Colorectal and Pancreatic Cancer Therapies

Reuters
·
Yesterday

Bollinger, Credo, Ambarella, Cipher, Incyte: Insider Moves Unveiled!

TIPRANKS
·
Oct 18

Top Executive Sells Incyte Stock: What This Means for Investors

TIPRANKS
·
Oct 18

Incyte EVP & General Counsel Sheila A. Denton Reports Disposal of Common Shares

Reuters
·
Oct 18

Incyte Canada: Health Canada Approves Opzelura (Ruxolitinib) Cream for Treatment of Atopic Dermatitis in Children Ages 2-11

THOMSON REUTERS
·
Oct 15

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Oct 15

Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000

Motley Fool
·
Oct 15

UBS Keeps Their Hold Rating on Incyte (INCY)

TIPRANKS
·
Oct 14

Incyte Corp. Stock Rises Monday, Still Underperforms Market

Dow Jones
·
Oct 14

Incyte announces results from its Phase 1 studies of INCA33890, INCB161734

TIPRANKS
·
Oct 13

Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025

Reuters
·
Oct 13

Ambarella, Planet Labs, Box, Conagra, Incyte: Major Stock Moves!

TIPRANKS
·
Oct 11

Incyte Is Maintained at Neutral by JP Morgan

Dow Jones
·
Oct 09

JPMorgan Adjusts Price Target on Incyte to $89 From $73, Maintains Neutral Rating

MT Newswires Live
·
Oct 09

RBC Capital Remains a Hold on Incyte (INCY)

TIPRANKS
·
Oct 09